LesiaKDropulicMD
Infectious Disease • Bethesda, MDTransplant/Immunocompromised States
Staff Clinician: The National Institutes of Health, NIAID, Laboratory of Infectious Diseases
Dr. Dropulic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
10 Center Dr
BG 10, Rm. 6D44D
Bethesda, MD 20892Phone+1 301-496-7675- Is this information wrong?
Education & Training
Johns Hopkins UniversityFellowship, Infectious Disease, 1992 - 1997
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1989 - 1992
Wayne State University School of MedicineClass of 1989
Certifications & Licensure
MD State Medical License 1992 - 2024
Clinical Trials
- The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise Start of enrollment: 2009 Oct 01
- Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection Start of enrollment: 2013 Sep 26
- Challenge Infection of Healthy Adult Volunteers With RSV A2 Start of enrollment: 2018 Feb 20
Publications & Presentations
PubMed
- 13 citationsAn influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans.Sarah F Andrews, Lauren Y Cominsky, Geoffrey D Shimberg, Rebecca A Gillespie, Jason Gorman, Julie E Raab, Joshua Brand, Adrian Creanga, Suprabhath R Gajjala, Sandeep N...> ;Science Translational Medicine. 2023 Apr 19
- 12 citationsAn influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.Alicia T Widge, Amelia R Hofstetter, Katherine V Houser, Seemal F Awan, Grace L Chen, Maria C Burgos Florez, Nina M Berkowitz, Floreliz Mendoza, Cynthia S Hendel, LaSo...> ;Science Translational Medicine. 2023 Apr 19
- 3 citationsLow-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.Kirsten E Lyke, Andrea A Berry, Kaitlin Mason, Azza H Idris, Mark O'Callahan, Myra Happe, Larisa Strom, Nina M Berkowitz, Mercy Guech, Zonghui Hu, Mike Castro, Manjula...> ;The Lancet. Infectious Diseases. 2023 May 1
- Join now to see all
Other Languages
- Ukrainian
Hospital Affiliations
NIH Clinical CenterBethesda, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
